Drugs / GE-IR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06247488 | Jan 2022 → Apr 2023 | substance abuse | Arbor Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GE-IR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06247488 ↗ |
| Route | Oral | “Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.” NCT06247488 ↗ |